Not a good buy right now for an impatient entry: trend structure is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no proprietary buy signals.
Price is already pushing above R1 (10.775) in pre-market (10.8069), leaving limited immediate upside to R2 (11.049) versus clearer downside back toward pivot (10.332).
Options positioning (very low OI put/call) leans bullish, but near-neutral volume put/call and elevated IV suggest conviction is mixed and options are expensive.
Fundamentals show revenue growth and better gross margin, but losses widened—reducing near-term “must-buy-now” urgency without a catalyst.
Technical Analysis
Trend: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) signals the broader trend is still down/weak despite a recent bounce.
RSI: RSI(6) ~59.9 is neutral-to-slightly-bullish; not overbought, but not a strong “oversold buy” either.
Levels: Pivot 10.332; pre-market ~10.8069 is above R1 10.775 (breakout attempt). Next resistance R2 11.049; supports S1 9.889 and S2 9.615.
Pattern-based odds: Similar-pattern projection implies mild next-day upside (+0.57%) but weakness over the next week (-2.19%), favoring caution on immediate entries.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Open Interest put/call = 0.22 is notably call-heavy (bullish positioning).
Volume: Volume put/call = 0.87 is closer to balanced, slightly put-leaning on the day (less bullish than OI suggests).
Activity: Today’s option volume (103) is elevated vs 30D average (127%); open interest also slightly above average (101%).
Volatility: IV30 ~55.15 vs historical vol ~28.59 implies options are pricing large moves (premium-rich), often seen when uncertainty is elevated.
IV rank/percentile: IV rank ~23.65 / percentile ~26.4 suggests IV is not extreme versus its own history, but still high relative to realized volatility.
No analyst rating or price target change data was provided, so there’s no confirmed recent Wall Street upgrade/downgrade trend to lean on.
Practical takeaway given the dataset: without visible analyst support/catalyst updates, the decision rests mainly on the mixed technical setup (bearish trend, improving momentum) and mixed fundamentals (growing sales, widening losses).
Positioning/flows: Hedge funds neutral; insiders neutral; no recent Congress trading data; no influential/political buys/sells indicated.
Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.060
Low
16
Averages
19.33
High
24
Current: 10.060
Low
16
Averages
19.33
High
24
Canaccord
John Young
Buy
maintain
$15 -> $17
AI Analysis
2025-07-16
Reason
Canaccord
John Young
Price Target
$15 -> $17
AI Analysis
2025-07-16
maintain
Buy
Reason
Canaccord analyst John Young raised the firm's price target on AngioDynamics to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn't much thesis changing news for the company during the quarter.
Lake Street
Buy
initiated
$24
2025-07-16
Reason
Lake Street
Price Target
$24
2025-07-16
initiated
Buy
Reason
Lake Street initiated coverage of AngioDynamics with a Buy rating and $24 price target. The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics' strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANGO
